These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25732945)

  • 1. [Current therapy of multiple sclerosis].
    Antonio García Merino J
    Med Clin (Barc); 2014 Dec; 143 Suppl 3():19-22. PubMed ID: 25732945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Oral treatments in multiple sclerosis].
    Meca-Lallana JE; Hernández-Clares R; Carreón-Guarnizo E
    Med Clin (Barc); 2014 Dec; 143 Suppl 3():23-9. PubMed ID: 25732946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].
    Elovaara I; Atula S; Erälinna JP; Färkkilä M; Pirttilä T; Remes A; Ruutiainen J; Varis T; ;
    Duodecim; 2010; 126(2):199-200. PubMed ID: 20405605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of interferon beta in the treatment of multiple sclerosis].
    Seeldrayers P
    Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic role of mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Pharmacol Ther; 2006 Jan; 109(1-2):198-209. PubMed ID: 16095713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Insight: interferon treatment in multiple sclerosis.
    Marrie RA; Rudick RA
    Nat Clin Pract Neurol; 2006 Jan; 2(1):34-44. PubMed ID: 16932519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
    Massacesi L; Tramacere I; Amoroso S; Battaglia MA; Benedetti MD; Filippini G; La Mantia L; Repice A; Solari A; Tedeschi G; Milanese C
    PLoS One; 2014; 9(11):e113371. PubMed ID: 25402490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus Statement on medication use in multiple sclerosis by the Spanish Society of Neurology's study group for demyelinating diseases.
    García-Merino A; Fernández O; Montalbán X; de Andrés C; Oreja-Guevara C; Rodríguez-Antigüedad A; Arbizu T;
    Neurologia; 2013; 28(6):375-8. PubMed ID: 23643683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guideline for the use of beta-interferons in patients with multiple sclerosis--a South African proposal.
    Multiple Sclerosis Advisory Committee of the Neurological Association of South Africa (NASA)
    S Afr Med J; 2004 Nov; 94(11):917-21. PubMed ID: 15587456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practical approach to immunomodulatory therapy for multiple sclerosis.
    Burks JS
    Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current description of multiple sclerosis].
    Río J; Montalbán X
    Med Clin (Barc); 2014 Dec; 143 Suppl 3():3-6. PubMed ID: 25732942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials.
    Sørensen PS
    Neurol Sci; 2003 Oct; 24 Suppl 4():S227-30. PubMed ID: 14598048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunology of relapse and remission in multiple sclerosis.
    Steinman L
    Annu Rev Immunol; 2014; 32():257-81. PubMed ID: 24438352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.